Damian Wild Selected Research

Glucagon-Like Peptide-1 Receptor

6/2022	Molecular Imaging in neuroendocrine neoplasias.
11/2021	New Directions in Imaging Neuroendocrine Neoplasms.
1/2021	Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
9/2020	Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging.
1/2020	Brunner's Gland Hyperplasia in a Patient after Roux-Y Gastric Bypass: An Important Pitfall in GLP-1 Receptor Imaging.
12/2018	Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.
1/2015	Preoperative Glucagon-like peptide-1 receptor imaging reduces surgical trauma and pancreatic tissue loss in insulinoma patients: a report of three cases.
2/2014	Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.
10/2013	Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.
1/2012	Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Damian Wild Research Topics

Disease

29	Neoplasms (Cancer) 06/2022 - 11/2004
23	Insulinoma 06/2022 - 12/2006
17	Neuroendocrine Tumors (Neuroendocrine Tumor) 02/2022 - 10/2006
8	Myocardial Ischemia (Ischemic Heart Diseases) 02/2018 - 11/2005
5	Thyroid Neoplasms (Thyroid Cancer) 06/2022 - 01/2019
5	Nesidioblastosis (Nesidioblastosis of Pancreas) 01/2021 - 12/2015
3	Neoplasm Metastasis (Metastasis) 11/2021 - 11/2015
3	Paraganglioma (Paragangliomas) 01/2021 - 09/2012
3	Disease Progression 01/2021 - 11/2015
3	Coronary Artery Disease (Coronary Atherosclerosis) 11/2018 - 06/2015
3	Ischemia 02/2018 - 06/2014
2	Pheochromocytoma 01/2021 - 09/2012
2	Hyperplasia 01/2021 - 01/2020
2	Hypoglycemia (Reactive Hypoglycemia) 01/2021 - 01/2020
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2017 - 06/2014
2	Myocardial Infarction 01/2017 - 06/2014
2	Carcinogenesis 07/2010 - 06/2007
2	Necrosis 06/2007 - 11/2004
1	medullary Thyroid cancer 11/2021
1	Colonic Diseases 08/2021
1	Bacterial Infections (Bacterial Infection) 08/2021
1	Infections 08/2021
1	Multiple Endocrine Neoplasia Type 1 01/2021
1	Multiple Endocrine Neoplasia (Multiple Endocrine Adenomatosis) 01/2021
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021
1	Neuroendocrine Carcinoma 01/2021
1	Amyloidosis 10/2020
1	Wasting Syndrome (Wasting Disease) 09/2020
1	Amaurosis Fugax 01/2017
1	Transient Ischemic Attack 01/2017
1	Stroke (Strokes) 01/2017
1	Wounds and Injuries (Trauma) 01/2015
1	Cicatrix (Scar) 06/2014
1	Death (Near-Death Experience) 06/2014
1	Primitive Neuroectodermal Tumors (PNET) 02/2014

Drug/Important Bio-Agent (IBA)

15	Glucagon-Like Peptide-1 ReceptorIBA 06/2022 - 12/2006
15	Somatostatin Receptors (Somatostatin Receptor)IBA 02/2022 - 10/2006
14	Radioisotopes (Radionuclides)IBA 02/2022 - 08/2007
14	Peptide Receptors (Peptide Receptor)IBA 02/2022 - 10/2006
13	Exenatide (Byetta)FDA Link 11/2021 - 12/2006
10	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 11/2021 - 10/2006
8	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 12/2006
7	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 09/2021 - 10/2006
5	Pentetic Acid (DTPA)FDA LinkGeneric 01/2021 - 12/2006
5	Troponin IIBA 11/2018 - 06/2015
4	Peptides (Polypeptides)IBA 01/2022 - 12/2006
4	Brain Natriuretic Peptide (Natrecor)FDA Link 02/2018 - 11/2005
3	Hormones (Hormone)IBA 06/2022 - 01/2021
3	minigastrinIBA 06/2022 - 01/2021
3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 11/2021 - 11/2004
3	LigandsIBA 11/2021 - 04/2008
3	68Ga-DOTA-exendin-4IBA 01/2020 - 12/2018
3	Biomarkers (Surrogate Marker)IBA 02/2018 - 04/2016
3	Octreotide (Sandostatin)FDA LinkGeneric 01/2017 - 10/2006
3	AcidsIBA 07/2010 - 10/2006
2	succinylated gelatinIBA 01/2020 - 01/2019
2	lutetium Lu 177 dotatateIBA 06/2019 - 01/2017
2	Edotreotide (SMT 487)IBA 06/2019 - 01/2018
2	PolygelineIBA 01/2019 - 07/2010
2	177Lu-DOTA-JR11IBA 01/2019 - 01/2017
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2019 - 01/2012
2	Troponin T (Troponin T1)IBA 11/2018 - 04/2016
2	trans-crotonin (CTN)IBA 02/2018 - 04/2016
2	TroponinIBA 02/2018 - 04/2016
2	Ga(III)-DOTATOCIBA 01/2018 - 01/2017
2	omega-Chloroacetophenone (Mace)IBA 01/2017 - 06/2014
2	gallium Ga 68 dotatateIBA 01/2017 - 03/2013
2	DOTA-PEG(4)-bombesin (7-14)IBA 02/2011 - 08/2007
1	Proteins (Proteins, Gene)FDA Link 11/2021
1	Pharmaceutical PreparationsIBA 08/2021
1	Benzoates (Benzoate)IBA 08/2021
1	Metronidazole (Metric)FDA LinkGeneric 08/2021
1	Phenobarbital (Luminal)FDA Link 08/2021
1	ChemokinesIBA 01/2021
1	3-Iodobenzylguanidine (Iobenguane)IBA 01/2021
1	CalciumIBA 01/2021
1	Prealbumin (Transthyretin)IBA 10/2020
1	DOTA(0)-Tyr(3)- 177Lu-octreotideIBA 09/2020
1	Fibroblast Growth Factor-23IBA 09/2020
1	Blood Glucose (Blood Sugar)IBA 09/2020
1	Phosphates (Orthophosphate)IBA 09/2020
1	Indium-111IBA 01/2020
1	IncretinsIBA 01/2020
1	Cholecystokinin B ReceptorIBA 01/2020
1	Insulin (Novolin)FDA Link 01/2020
1	SolutionsIBA 01/2020
1	pentetreotide (OctreoScan)FDA Link 05/2019
1	phosphoramidonIBA 01/2019
1	ThiorphanIBA 01/2019
1	Dihydroxyphenylalanine (Dopa)IBA 01/2019
1	Complement System Proteins (Complement)IBA 06/2015

Therapy/Procedure

20	Therapeutics 02/2022 - 12/2006
3	Precision Medicine 01/2021 - 01/2019
3	Radiotherapy 02/2014 - 06/2007
1	Transplantation 01/2021
1	Injections 01/2020
1	Bariatric Surgery 01/2020
1	Gastric Bypass (Roux-en-Y Gastric Bypass) 01/2020
1	Carotid Endarterectomy 01/2017
1	Stents 06/2014